Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.33 |
| ▸ | KDM4A | O75164 | 1/20 | 0.33 |
| ▸ | KDM5A | P29375 | 1/20 | 0.33 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.33 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.33 |
| ▸ | SRC | P12931 | 3/20 | 0.33 |
| ▸ | TGFBR1 | P36897 | 3/20 | 0.33 |
| ▸ | PDE4A | P27815 | 1/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.33 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7064238 | 0.88 | MEN1 (0.38) | MEN1RAB9AKMT2APOLBPDE4A | |
| Potassium Ion SCHEMBL7063083 | 0.88 | MEN1 (0.33) | MEN1RAB9AKMT2APOLBSRC | |
| SCHEMBL7064241 | 0.74 | ATM (0.43) | MEN1RAB9AKMT2APOLBKDM4C | |
| SCHEMBL6435715 | 0.73 | CYP2D6 (0.65) | — | |
| SCHEMBL6435710 | 0.73 | CYP2D6 (0.65) | — | |
| SCHEMBL2053701 | 0.71 | CNR2 (0.39) | MEN1KMT2ASMN1; SMN2MET | |
| Hydrochloric Acid SCHEMBL2053752 | 0.70 | CNR2 (0.39) | MEN1KMT2ASMN1; SMN2MET | |
| SCHEMBL16593542 | 0.69 | PDE4D (0.35) | MEN1RAB9AKMT2APOLBKDM4C | |
| SCHEMBL2998359 | 0.66 | CDK5 (0.50) | MEN1RAB9AKMT2APOLBSRC | |
| SCHEMBL2052831 | 0.65 | NPSR1 (0.39) | MEN1KMT2ASMN1; SMN2KDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1257276-B1 | ANTIVIRAL AZAINDOLE DERIVATIVES | BRISTOL MYERS SQUIBB CO (US) | 2005-12-28 | — | — | EP | disclosed |
| US-6900323-B2 | Antiviral azaindole derivatives | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-05-31 | — | — | US | disclosed |
| EP-1257276-A4 | ANTIVIRAL AZAINDOLE DERIVATIVES | BRISTOL MYERS SQUIBB CO (US) | 2004-10-27 | — | — | EP | disclosed |
| US-20040023982-A1 | Antiviral azaindole derivatives | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2004-02-05 | — | — | US | disclosed |
| US-6632819-B1 | HIV and AIDS | BRISTOL-MYERS SQUIBB COMPANY | 2003-10-14 | — | — | US | disclosed |
| EP-1257276-A1 | ANTIVIRAL AZAINDOLE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-11-20 | — | — | EP | disclosed |
| US-6476034-B2 | AIDS THERAPY | BRISTOL-MYERS SQUIBB COMPANY | 2002-11-05 | — | — | US | disclosed |
| US-20020119982-A1 | Antiviral azaindole derivatives | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2002-08-29 | — | — | US | disclosed |
| US-20020061892-A1 | Antiviral azaindole derivatives | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2002-05-23 | — | — | US | disclosed |
| WO-2001062255-A1 | ANTIVIRAL AZAINDOLE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020119982-A1 | Antiviral azaindole derivatives | ZC3HAV1, MAVS, AZI2 | MEN1 4153/4885RAB9A 1982/4885KMT2A 941/4885 |
| US-20020061892-A1 | Antiviral azaindole derivatives | ZC3HAV1, MAVS, AZI2 | MEN1 4153/4885RAB9A 1982/4885KMT2A 941/4885 |
| US-20040023982-A1 | Antiviral azaindole derivatives | ZC3HAV1, MAVS, EIF2AK2 | MEN1 3938/4885RAB9A 2229/4885KMT2A 997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.